Ac-E(Chol)E(Chol)E(Chol)-HHHHH-YGRKKRRQRRR
Sequence: Tat peptide core with variable His repeats and cholesterol–glutamate lipid (see Fig. 4A for exact composition)
| Experiment Id | EXP000587 |
|---|---|
| Paper | Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine |
| Peptide | Ac-E(Chol)E(Chol)E(Chol)-HHHHH-YGRKKRRQRRR |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | varied (micelle formulation) |
| Rna Concentration | ~50 nM (in vitro) |
| Mixing Ratio | N/P ≥10:1 |
| Formulation Format | Self-assembled lipid-modified CPP micelles |
| Formulation Components | Lipid-modified CPP + siULK1 ± narciclasine |
| Size Nm | 96.00 |
| Zeta Mv | 15.00 |
| Model Scope | in_vivo |
| Model Type | in vitro / in vivo |
| Cell Lines Or Primary Cells | HepG2; Huh-7; Bel-7402 |
| Animal Model | HepG2 xenograft nude mice |
| Administration Route | Intravenous |
| Output Type | ULK1 knockdown; uptake; tumor growth inhibition |
| Output Value | Robust ULK1 knockdown and tumor suppression |
| Output Units | |
| Output Notes | Selected lead formulation for all subsequent functional and in vivo studies |
| Toxicity Notes | Good safety profile |
| Curation Notes |